首页 › 基金 › Vestal Point Capital, LP › TRVI
Vestal Point Capital, LP 对 TRVI 的持仓历史
TREVI THERAPEUTICS INC · 医疗保健
Vestal Point Capital, LP 在 Q3 2026 的 13F 申报中披露持有 TRVI(TREVI THERAPEUTICS INC)1,495,000 股,市值约 US$21.4M,约占其申报组合的 0.55%,在其申报持仓中市值排名第 28 位。 Vestal Point Capital, LP 最近 3 个申报季度中有 3 个季度披露了 TRVI 持仓,最早可追溯至 Q1 2026。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Vestal Point Capital, LP 对 TRVI 的持仓演变
Vestal Point Capital, LP 于 Q1 2026 首次披露 TRVI 持仓:2,166,504 股(约 US$25.8M)。 该持仓在 Q2 2026 达到峰值 3,100,000 股,市值约 US$57.8M。 在 3 次申报中,Vestal Point Capital, LP 1 次增持、1 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 1,495,000 股、市值约 US$21.4M,环比减持 -1,605,000 股。。 持仓曾出现大幅变动:Q2 2026 增持约 43% (随后一个季度股价下跌 23%)、Q3 2026 减持约 52% (随后一个季度股价下跌 7%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2026 | 2.17M | $25.85M | 新进 |
| Q2 2026 | 3.10M | $57.81M | 增持 |
| Q3 2026 | 1.50M | $21.41M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 TRVI 与 13F 数据
TRVI(TREVI THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 55 只申报持有 TRVI,申报仓位最大的包括:NEA Management Company, LLC (US$189.3M), Frazier Life Sciences Management, L.P. (US$136.6M), Vivo Capital, LLC (US$60.6M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 TRVI 的基金
- NEA Management Company, LLC 13.22M 股 · $189.34M · Q3 2026
- Frazier Life Sciences Management, L.P. 9.54M 股 · $136.60M · Q3 2026
- Vivo Capital, LLC 4.23M 股 · $60.57M · Q3 2026
- MPM BioImpact LLC 2.98M 股 · $42.66M · Q3 2026
- Soleus Capital Management, L.P. 2.73M 股 · $39.06M · Q3 2026
- First Light Asset Management, LLC 2.39M 股 · $34.19M · Q3 2026
- Artia Global Partners LP 2.21M 股 · $31.66M · Q3 2026
- ACORN CAPITAL ADVISORS, LLC 2.14M 股 · $30.71M · Q3 2026
- Affinity Asset Advisors, LLC 1.80M 股 · $25.78M · Q3 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.74M 股 · $24.96M · Q3 2026
- Saturn V Capital Management LP 1.57M 股 · $22.54M · Q3 2026
- Siren, L.L.C. 1.52M 股 · $21.82M · Q3 2026
更多关于 Vestal Point Capital, LP
常见问题
How long has Vestal Point Capital, LP held TRVI?
Vestal Point Capital, LP has disclosed TRVI holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Vestal Point Capital, LP's current position in TRVI?
As of Q3 2026, Vestal Point Capital, LP holds 1.50M shares of TRVI (TREVI THERAPEUTICS INC), valued at $21.41M, representing 0.55% of its reported portfolio and ranking #28.
Has Vestal Point Capital, LP been buying or selling TRVI?
In the latest 13F filing (Q3 2026), Vestal Point Capital, LP reduced its position in TRVI. The position peaked in Q2 2026 at 3.10M shares.
Which other funds hold TRVI?
Other major institutional holders of TRVI include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Vivo Capital, LLC, among 55 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.